# Chugai Pharmaceutical

Source: https://onco.cc/companies/chugai/  
OnCo record `chugai` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chugai is a Tokyo pharmaceutical company majority-owned by Roche that discovered alectinib for ALK-positive lung cancer and sells Roche's cancer medicines in Japan.

## Summary

Chugai Pharmaceutical, listed in Tokyo and majority-owned by Roche since 2002 while remaining a separately listed company, is one of Japan's largest drug makers and its most important source of cancer medicines. It discovered the ALK inhibitor alectinib (Alecensa), developed worldwide with Roche, and markets Roche's oncology portfolio in Japan, including atezolizumab, trastuzumab, bevacizumab and polatuzumab vedotin, alongside its own antibody engineering platforms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Chugai; 中外製薬
- Tags: ctgov-sponsor
- HQ: Tokyo
- Type: pharma
- Website: https://www.chugai-pharm.co.jp/english/

## Sources

- Official website: https://www.chugai-pharm.co.jp/english/
- ClinicalTrials.gov: trials led by Chugai Pharmaceutical: https://clinicaltrials.gov/search?lead=Chugai%20Pharmaceutical
- Wikipedia: https://en.wikipedia.org/wiki/Chugai_Pharmaceutical_Co.

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Polatuzumab vedotin](https://onco.cc/drugs/polatuzumab-vedotin/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/chugai.json